Small Alzheimer's hopeful biotech nabs $15M series B for metabolic drug approach

A small private biotech has raised a modest series B as it continues to test its idea that memory-wasting Alzheimer's disease (AD) can be beaten back by focusing on fat and sugar metabolism in the brain.

North Carolina-based T3D Therapeutics has got off a $15 million series B, which adds to its support from the National Institute on Aging (part of the National Institutes of Health) to start work on the phase 2 drug T3D-959 in AD.